You are here: Industry Insights > Janssen

News List

Janssen’s Phase 1 Results for Teclistamab Suggest Deep, Durable Responses americanpharmaceuticalreview
May 28, 2021
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a manageable safety profile according to new data at ASCO.
Talquetamab shows promise in multi-drug refractory multiple myeloma patients europeanpharmaceuticalreview
May 27, 2021
New Phase I data shows 65 percent of triple-class and 83 percent of penta-drug refractory multiple myeloma patients responded to talquetamab.
Janssen’s Erleada maintains quality of life for prostate cancer patients pharmatimes
May 27, 2021
Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data.
Industry hustling to ensure supply of recombinant vector COVID-19 vaccines europeanpharmaceuticalreview
May 26, 2021
A new report suggests pharma is working hard to combat worldwide viral vectors shortage that could threaten the COVID-19 vaccine rollout.
EC approves Ponvory for relapsing MS pharmatimes
May 26, 2021
The European Commission (EC) has cleared Janssen’s Ponvory for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease.
FDA approves Janssen’s Rybrevant pharmatimes
May 25, 2021
The US Food and Drug Administration (FDA) has approved Janssen’s Rybrevant as the first treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
European Commission approves PONVORY™ --- A Once Daily Oral Treatment for Adults with Relapsing Forms of Multiple Sclerosis americanpharmaceuticalreview
May 25, 2021
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by ...
Imbruvica®-based regimens induce lasting remissions in leukaemia trials europeanpharmaceuticalreview
May 21, 2021
Imbruvica® (ibrutinib) plus ventoclax and single-agent Imbruvica induced remissions lasting up to seven years in first-line treatment of chronic lymphocytic leukaemia.
NICE turns down Janssen's Erleada pharmatimes
May 21, 2021
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy (ADT) for treating prostate cancer.
Janssen inks inflammatory disease collaboration with Mestag Therapeutics pharmatimes
May 19, 2021
Janssen, the pharma division of Johnson & Johnson, has entered an agreement with Cambridge, UK-based Mestag Therapeutics to research and develop novel fibroblast targets for the treatment of inflammatory disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page